Novo Nordisk revenue and financials

NOVO.B · Nasdaq Copenhagen · DKK

kr 250.70Change from previous close: +2.10%Absolute change: +kr 5.15

Close · October 7, 2026

In the fiscal year ended December 2025, Novo Nordisk reported revenue of kr 309.06B (+6.43% year over year). Net income was kr 102.43B, a net margin of 33.1%.

Annual revenue · 2025: kr 309.06B
  1. kr 122.02B2019
  2. kr 126.95B2020
  3. kr 140.8B2021
  4. kr 176.95B2022
  5. kr 232.26B2023
  6. kr 290.4B2024
  7. kr 309.06B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+6.43%
2025 vs 2024
Net income growth
+1.43%
2025 vs 2024
Net margin
33.1%
2024: 34.8%

Financial data

Amounts in millions of DKK; per-share values in DKK; shares in millions.

Cash flow · Quarterly
ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Operating cash flow55,19924,0847,61946,10741,77424,73012,30143,85050,50314,3149,55140,966
Depreciation and amortization3,6053,5133,0853,2373,7443,7592,0762,0202,0372,1576552,525
Capital expenditure-12,675-11,311-18,429-13,628-14,661-13,422-16,101-12,119-10,470-8,474-9,407-5,828
Investing cash flow-12,764-11,712-42,812-15,425-14,118-5,979-91,216-20,904-20,7313,956-14,717-13,243
Financing cash flow-19,132-17,43329,467-17,096-47,3494,61836,835-18,40116,683-26,382-10,116-19,832
Dividends paid0.0-35,3120.0-16,663174-35,274—-15,583—-28,557—-13,430
Share repurchases-3,499-2,4000.00.00.0-1,388-7,491-2,405-7,449-2,836-9,761-6,141
Debt issued18,77215,97730,62071345,23527,36344,75911934,513———
Debt repaid-26,112-1,232-1,153-1,146-64,857-12,032-433-532-5,053-317-355-261
Effect of exchange rates52.0-27610663.0-810-86.0717-34842.044.0-209418
Net change in cash23,355-5,337-5,62013,649-20,50323,283-41,3634,19746,497-8,068-15,4918,309
Free cash flow42,52412,773-10,81032,47927,11311,308-3,80031,73140,0335,84014435,138
Levered free cash flow25,51412,839-34,94829,842-23,79525,2553,83625,60326,8816,366-13,95629,516